Clinical Trial Detail

NCT ID NCT01298570
Title Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

rectum adenocarcinoma

colon adenocarcinoma

Therapies

Fluorouracil + Irinotecan + Leucovorin

Regorafenib

Age Groups: adult

No variant requirements are available.